Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I–II papillary serous endometrial cancer

Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women

“…We found a five-year overall survival of between 53% and 58% for early-stage, and from 0-39% for advanced-stage (III and IV), disease. 6,[13][14][15][16][17][18][19] The median age of our patient with USC at the time of diagnosis was similar to that seen in other studies, but older than the median age of women with endometrioid uterine cancer. 4,6,11,[20][21][22] Abnormal uterine bleeding was the most common clinical presentation with USC, just as it is in endometrioid uterine cancer.…”

“…This recurrence rate is similar to that reported in other studies. [14][15][16][17][18] The recurrence rates were higher in patients who received chemotherapy only, possibly owing to the fact that only patients with advanced-stage disease (III and IV) received chemotherapy as a single treatment modality. As in other studies, recurrence risk correlated with the stage of disease.…”

“…As in other studies, recurrence risk correlated with the stage of disease. 6,[13][14][15][16][17][18][19] Relapse rates varied from 23% for stage I, to 100% for stage IV, patients. No significant difference could be demonstrated for recurrence rates relating to the adjuvant treatment that patients with different stages of disease received.…”

“…6,[9][10][11][12] Survival varies with each stage, from 45-90% for early-stage (I and II), and 0-30% for advanced stage (III and IV), disease. 6,[13][14][15][16][17][18][19] These tumours are not well understood owing to the low incidence and limited data published thereon. Surgery is the cornerstone of treatment, but a lack of prospective studies leaves uncertainty as to the role of adjuvant therapy.…”

Early stage uterine serous carcinoma: Management updates and genomic advances

“…With regard to management of stage I USC, a recent retrospective study from Memorial Sloan Kettering of 41 women with early stage disease treated with 6 cycles of intravenous carboplatin/paclitaxel and vaginal brachytherapy demonstrated excellent 5-year progressionfree (85%) and overall survival rates (90%) [67]. Only four of 34 stage I patients experienced a recurrence (11.7%) after a median follow-up of 58 months, and two isolated pelvic recurrences were salvaged.…”